Improving the Therapeutic Ratio in Head and Neck Cancer
- 1st Edition, Volume 6 - October 5, 2019
- Latest edition
- Editors: Benjamin Bonavida, Randall J. Kimple
- Language: English
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents… Read more
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.
The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.
This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
- Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic
- Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways
- Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
Cancer researchers; oncologists; graduate students
1. Overview of head and neck cancer management2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer3. Targeting the PI3K/mTOR pathway4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy5. Overcoming head and neck cancer stem cells6. TAM Family proteins and therapy resistance7. Eph/Ephrin family proteins and theapy resistance8. Metabolic reprogramming to modulate therapeutic sensitivity9. FGFR and cMET10. Targeting GPCRs in HNC11. Improving the response to immunotherapy12. Chk1/2 inhibition in radiation and cetuximab resistance
- Edition: 1
- Latest edition
- Volume: 6
- Published: October 5, 2019
- Language: English
BB
Benjamin Bonavida
Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).
Affiliations and expertise
Professor, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, USARK
Randall J. Kimple
Dr. Kimple completed his MD, PhD in Pharmacology, and residency in Radiation Oncology at the University of North Carolina. He is an Associate Professor of Human Oncology at the University of Wisconsin School of Medicine and Public Health where he is a member of the Multidisciplinary Head and Neck Program and the Wisconsin Head and Neck Cancer SPORE Grant. He runs a translational research lab focused on understanding the molecular basis of therapeutic resistance in head and neck cancer.
Affiliations and expertise
Associate Professor, Department of Human Oncology, UW Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USARead Improving the Therapeutic Ratio in Head and Neck Cancer on ScienceDirect